pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Keytruda · news · pharmadog
← back to Keytruda
News mentioning Keytruda
171
stories
15h
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
biopharma dive
22h
Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
biospace
1d
As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
biospace
1d
Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
biospace
5d
Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
stat
5d
After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward
stat
7d
BioNTech mRNA cancer immunotherapy misses first objective in key study
biopharma dive
7d
BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival
biospace
7d
STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more
stat
7d
Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
biospace
7d
BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence
fiercebiotech
8d
BMS’ Phase 3 win for lung drug clouded by high-dose miss
biospace
8d
Pharma’s $500B patent problem will come in waves — not as a cliff
biopharma dive
11d
STAT+: Pharma’s free lunches for doctors boost inappropriate prescribing, analysis finds
stat
11d
STAT+: Up and down the ladder: The latest comings and goings
stat
11d
STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more
stat
12d
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
biospace
12d
Merck barred from making subcutaneous Keytruda in 8 European countries
biospace
12d
STAT+: Pharmalittle: We’re reading about PhRMA suing Trump, biotech frustration over tariffs, and more
stat
13d
Recon: FDA identifies four deaths in Newron schizophrenia drug trials; Dutch court blocks subcutaneous Keytruda in eight Europea...
raps
13d
STAT+: In small trial, optogenetics restores some vision lost to retinitis pigmentosa
stat
13d
Dutch court blocks subcutaneous Keytruda in eight European countries
endpoints
13d
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
biopharma dive
13d
STAT+: Merck suffers a setback in Europe over its new Keytruda formulation
stat
13d
5 biggest venture capital raises of Q3 2026
biospace
15d
Significant stock movers of September: Viking soars, Longeveron slides
biospace
18d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
18d
Varda raises $251M to leverage gravity in space for drug production
biospace
19d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
21d
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
← prev
page 1 of 6
next →
